Sutro Biopharma, Inc
111 Oyster Point Blvd
South San Francisco
California
94080
United States
Tel: 650.881.6500
Website: http://www.sutrobio.com/
Email: general@sutrobio.com
About Sutro Biopharma, Inc
Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies.
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro’s platform technology also enabled the spin out of Vaxcyte (Nasdaq: PCVX) and the creation of VAX-24, a 24-valent pneumococcal conjugate vaccine in clinical studies for the prevention of invasive pneumococcal disease. Sutro’s rational design and precise protein engineering has enabled six product candidates in the clinic.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.
The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
Stock Symbol: STRO
Our Purpose Is Our Patients
175 articles about Sutro Biopharma, Inc
-
Sutro Biopharma to Participate in Three Upcoming Investor Conferences
11/2/2021
Sutro Biopharma, Inc. today announced that Chief Executive Officer, Bill Newell , will participate in three upcoming virtual investor conferences.
-
Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China
10/12/2021
Sutro Biopharma, Inc. and BioNova Pharmaceuticals Limited today jointly announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate (ADC), for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
-
Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
9/30/2021
Sutro Biopharma, Inc. today announced that Merck has extended the research term for the first cytokine derivative program under the 2018 Merck Agreement, for an additional two years.
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 17, 2021
9/17/2021
Sutro Biopharma, Inc. announced that on September 15, 2021, the Compensation Committee of Sutro's Board of Directors granted restricted stock unit awards representing an aggregate of 150,000 shares of Sutro common stock and stock options to purchase an aggregate of 145,000 shares of Sutro common stock to 3 new employees.
-
Sutro Biopharma Announces Expansion of Leadership Team
9/16/2021
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced the appointment of two executives to the Company's leadership team.
-
With multiple job openings across the industry, biotech and biopharma employers have to come up with different strategies to retain top talent. -
Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
9/1/2021
Sutro Biopharma, Inc. today announced that Bill Newell , Chief Executive Officer, will participate in the 2021 Wells Fargo Securities Healthcare Conference during a virtual fireside chat on Thursday, September 9, at 3:20 p.m. ET / 12:20 p.m. PT.
-
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
8/18/2021
Sutro Biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα).
-
BioSpace Movers & Shakers, Aug. 13
8/13/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones
8/9/2021
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported its financial results for the quarter ended June 30, 2021, its recent business highlights, and provided a preview of anticipated selected milestones in the second half of 2021.
-
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
8/9/2021
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced the appointment of Jane Chung to the newly-created position of Chief Commercial Officer, effective August 9, 2021.
-
Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference
7/29/2021
Sutro Biopharma, Inc. announced that Chief Executive Officer, Bill Newell, will participate in a panel titled "ADCs – Take Me to Your Tumor" at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, at 2:20 p.m. ET / 11:20 a.m. PT.
-
Sutro Biopharma to Participate in Two Virtual Investor Conferences in June
6/15/2021
Sutro Biopharma, Inc. today announced that Chief Executive Officer, Bill Newell , will participate in two virtual investor conferences in June.
-
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
6/1/2021
Sutro Biopharma, Inc. announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, related to a patient enrollment achievement in the Phase 1 dose escalation and expansion study of M1231 in adult patients with metastatic solid tumors, including non-small cell lung cancer and esophageal squamous cell carcinoma.
-
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry. -
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
5/19/2021
- Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months - One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration of response on the five confirmed responders was 5.8 months - Data on STRO-002 from the dose-escalation cohort to be presented as a poster at ASCO and available as part of the Company Corporate Presentation has a cut-off date of April 23, 2021
-
If these companies are any indication, it appears that the biopharma industry will be a hybrid of virtual and physical workforces, and with this comes a whole new set of risks. -
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
5/14/2021
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will present at two upcoming virtual investor conferences
-
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
5/7/2021
- Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is ongoing - Merck initiated IND-enabling toxicology studies for the first program under the cytokine derivatives collaboration resulting in a $15 million milestone payment earned in April 2021 - EMD Serono began a Phase 1 study for the bispecific MUC1-EGFR ADC, M1231, during the first quarter of 2021
-
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
4/20/2021
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced the promotion of Chief Scientific Officer Trevor Hallam, Ph.D., to President of Research.